Goldfinch Bio Was A Clinical Stagebiotechnology Company Based In Cambridgemassachusettsfounded In 2016 By Third Rock Venturesthecompany Focused On Developing Precision Medicines Specifically For Kidney Diseasesaiming To Improvethequality Of Lifefor Affected Individualsgoldfinch Bio Utilized A Genomics Based Approachleveraging Its Proprietary Kidney Genomeatlaskgaa Cto Discover Treatments Tailored To Theuniquecauses Of Kidney Diseasethecompany S Lead Candidatewas Gfb 887A Trpc5 Ion Channel Inhibitor Intended For Treating Kidney Diseaseswhich Was Set To Advanceinto Phase2 Clinical Studiesadditionallygoldfinch Bio Was Developing Gfb 024A Monoclonal Antibody For Rareand Metabolic Kidney Diseasesthecompany Also Established A Strategic Collaboration With Gilead Sciencesincto Further Advancenovel Therapies For Kidney Disease
